Teva Announces Licence Agreement With Alder For Anti-CGRP Antibodies Patent

(RTTNews) - Teva Pharmaceutical Industries Ltd., (TEVA) Monday announced that its subsidiary, Teva Pharmaceuticals International GmbH., has signed a global license agreement with Alder BioPharmaceuticals Inc. (ALDR).

The agreement validates Teva's IP and resolves Alder's opposition to Teva's European Patent No. 1957106 B1, with respect to anti-calcitonin gene-related peptide antibodies and methods for their use.

As per the agreement, Alder has received a non-exclusive license to Teva's anti-CGRP antibodies patent portfolio to develop, manufacture and commercialize eptinezumab in the U.S. and worldwide, excluding Japan and Korea. In exchange, Alder has agreed to withdraw its appeal before the European Patent Office; make an immediate one-time payment of $25 million to Teva; and a second one-time payment of $25 million upon the approval of a biologics license application for Alder's eptinezumab with the U.S. Food and Drug Administration or of an earlier equivalent filing with a regulatory authority elsewhere in the license territory in which any Teva licensed patents exist.

Further Alder agreed that following commercial launch of eptinezumab, it would pay $75 million at each of two sales-related milestones at $1 billion and $2 billion in sales achieved in a calendar year and to provide certain royalty payments on net sales at rates from 5 to 7 percent.